Indication intelligence, analysis and sector perception

Pluristem (PSTI) a Memorandum of Understanding with Fukushima Medical University (FMU)

December 3, 2015 7:39am

A collaboration to study PLX-R18 in Acute Radiation Syndrome; PSTI will contribute PLX-R18 cells and scientific knowledge, while FMU will conduct the studies, and provide the required resources. Going nowhere fast and short on the upside!

Effects of PLX-R18 will be studied in the lungs, gastrointestinal tract, skin, and bone marrow following exposure to catastrophic levels of radiation following signing a Memorandum of Understanding (MOU) for collaboration with Fukushima Medical University for morbidities following radiotherapy in cancer patients.

The collaboration will proceed alongside research supported by the U.S. National Institutes of Health (NIH), which is studying PLX-R18 as a potential treatment for the hematologic component of ARS.

The Bottom Line: Data from a preclinical study, published in the peer-reviewed scientific journal PLOS One, suggest that PLX-R18 cells, administered intramuscularly, may be a highly effective off-the-shelf therapy for bone marrow failure following total body exposure to high doses of radiation.

PSTI closed at $1.43 and has been “wallowing” under a $1.00 since 9/23/15. Early study after study and it hasn’t advanced much of anything. Reviewing the institutional holdings … it’s at a measly 6.40% - says a lot.

PLX-R18 is PSTI’s second cell therapy product in development. It is already being studied as a treatment for bone marrow that is unable to produce blood cells because of a variety of causes including: ARS; unsuccessful hematopoietic cell transplants; certain cancers; radiotherapy and certain chemotherapies used to treat some cancers; and immune-mediated bone marrow failure.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 24 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.